Chinese commercial-stage, oncology-focused biotech firm BeiGene on Monday announced that it is raising gross proceeds of approximately $2.08 billion through a registered direct offering.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
